Insider · CIK 0001621788

Satvat Ali J.

Reports to the SEC for 4 companies · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001621788

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-22	BBIOBridgeBio Pharma, Inc.A Award	Director	AAward	+3,990 sh	—	—	169,983
2026-06-22	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,277 sh	—	—	5,277
2026-06-05	CHRSCoherus Oncology, Inc.A Award	Director	AAward	+30K sh	—	—	30,000
2026-06-05	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+60K sh	—	—	60,000
2025-06-20	BBIOBridgeBio Pharma, Inc.A Award	Director	AAward	+6,589 sh	—	—	165,993
2025-06-20	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,425 sh	—	—	8,425
2025-06-12	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+112K sh	—	—	112,000
2024-12-30	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+79.7K sh	$10.99	+$876K	79,702
2024-12-30	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+39.9K sh	$16.68	+$665K	119,553
2024-12-30	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+39.9K sh	$26.21	+$1.04M	159,404
2024-12-30	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−79.7K sh	—	—	0
2024-12-30	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−39.9K sh	—	—	0
2024-12-30	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−39.9K sh	—	—	0
2024-06-21	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+26K sh	—	—	26,014
2023-06-21	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+51.5K sh	—	—	51,501
2022-06-22	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+105K sh	—	—	104,921
2021-06-17	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+38.9K sh	—	—	38,895
2021-01-26	Eidos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.5K sh	—	—	0
2021-01-26	Eidos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.5K sh	—	—	0
2021-01-26	Eidos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−43.1K sh	—	—	0
2021-01-26	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+39.9K sh	—	—	39,851
2021-01-26	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+39.9K sh	—	—	39,851
2021-01-26	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+79.7K sh	—	—	79,702
2020-06-02	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+112K sh	—	—	112,422
2020-05-27	Eidos Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+21.5K sh	—	—	21,528
2020-01-10	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-12-12	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+82.9K sh	—	—	82,878
2019-07-03	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+882K sh	$29.90	+$26.4M	24,575,501
2019-06-12	Eidos Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+21.5K sh	—	—	21,528
2019-05-24	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+1.1M sh	$25.93	+$28.6M	23,693,148
2019-01-11	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2018-12-10	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+38K sh	$13.29	+$505K	22,586,636
2018-12-10	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+2,664 sh	$13.96	+$37.2K	22,589,300
2018-12-07	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+36.3K sh	$13.94	+$506K	22,543,787
2018-12-07	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+4,860 sh	$14.36	+$69.8K	22,548,647
2018-12-06	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+39K sh	$13.34	+$520K	22,507,473
2018-12-05	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+1.1M sh	$14.01	+$15.5M	22,468,503
2018-12-03	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+1.75M sh	$15.50	+$27.1M	21,364,655
2018-07-01	Eidos Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+43.1K sh	—	—	43,056
2018-06-22	Eidos Therapeutics, Inc.C Conversion	Director	CConversion	+18.8M sh	—	—	18,826,417
2018-06-22	Eidos Therapeutics, Inc.F Tax Payment	Director	FTax Payment	−212K sh	$17.00	−$3.6M	18,614,655
2018-06-22	Eidos Therapeutics, Inc.P Purchase	Director	PPurchase	+1M sh	$17.00	+$17M	19,614,655
2018-06-22	Eidos Therapeutics, Inc.WarrantsX Exercise of In-Money	Director	XExercise of In-Money	−332K sh	—	—	0
2018-06-22	Eidos Therapeutics, Inc.Series B Convertible Preferred StockX Exercise of In-Money	Director	XExercise of In-Money	+332K sh	—	—	2,909,029
2018-06-22	Eidos Therapeutics, Inc.Series B Convertible Preferred StockC Conversion	Director	CConversion	−2.91M sh	—	—	0
2018-06-22	Eidos Therapeutics, Inc.Series Seed Preferred StockC Conversion	Director	CConversion	−12.8M sh	—	—	0
2018-02-01	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2017-05-17	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2016-05-24	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2015-04-01	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000

Recent filings

Accepted (ET)
Jun 244
Satvat Ali J.0001470831-26-000625
SEC(opens sec.gov)
Jun 94
Satvat Ali J.0001610717-26-000206
SEC(opens sec.gov)
Jun 244
Satvat Ali J.0000950170-25-089665
SEC(opens sec.gov)
Jun 134
Satvat Ali J.0001610717-25-000222
SEC(opens sec.gov)
Dec 314
Satvat Ali J.0000950170-24-141676
SEC(opens sec.gov)
Jun 254
Satvat Ali J.0000950170-24-077450
SEC(opens sec.gov)
Jun 234
Satvat Ali J.0001209191-23-039391
SEC(opens sec.gov)
Jun 244
Satvat Ali J.0001209191-22-039262
SEC(opens sec.gov)
Jun 224
Satvat Ali J.0000899243-21-025414
SEC(opens sec.gov)
Jan 284
Satvat Ali J.0000899243-21-003647
SEC(opens sec.gov)

Companies

Address

C/O KOHLBERG KRAVIS ROBERTS & CO. L.P. 2800 SAND HILL ROAD

MENLO PARK, CA, 94025